Alveolar clefts

26 Alveolar clefts







Historical perspective


Although the visible soft-tissue deformity associated with cleft lip and palate has been described and treated for centuries, the importance of treating the underlying skeletal pathology has only recently been realized. Primary bone grafting in infancy and early childhood was advocated by Schmid and others in the mid 20th century,15 but soon fell into disfavor, with long-term follow-up demonstrating iatrogenic impairment of facial growth. In the midst of this backlash to alveolar grafting, Boyne introduced the concept of secondary alveolar bone grafting in the 1960s, advocating treatment towards the end of the first decade of life to minimize growth impairment while still supporting eruption of the adult dentition.6 The same decade, Skoog published his experience with “boneless bone grafting,” which was the birth of the concept of GPP.7


All of these three treatment options of alveolar reconstruction – primary grafting, secondary grafting, and GPP – are currently practiced in modern cleft care; however most practitioners would accept that secondary bone grafting remains the most widely accepted or “gold standard.” Despite this predominance of secondary grafting, treatment of the alveolar cleft remains the most controversial topic of discussion at national cleft meetings.8 New technology in this century has introduced even more variables in the form of inductive proteins that could avoid the need for graft material, and devices that can generate bone formation through the principles of distraction osteogenesis.


Practitioners in cleft care should understand the pros and cons of all options of alveolar cleft treatment regardless of their protocol of choice. Only in this way can the merits of new technologies and treatment protocols be fairly evaluated. The overriding goals of alveolar cleft treatment should be shared by all treatments and are listed in Table 26.1. The purpose of this chapter is to introduce the reader to the concepts of each treatment and to discuss the available literature regarding the success of each in achieving the treatment goals.


Table 26.1 Goals of treatment of the alveolar cleft








Basic science/disease process



Anatomy of the alveolar cleft


The alveolar cleft is more than a linear gap in the maxillary arch. With soft tissue removed the cleft is best visualized as a tornado, increasing in size from incisal to apical, becoming widest as it extends into the nasal cavity and distorts the surrounding anatomy (Fig. 26.1). The soft-tissue distortion caused by this skeletal deficiency can be minimized by a correctly performed cleft lip repair, but not completely eradicated. In the patient with an untreated alveolar cleft, the alar base of the nose lacks the bony support of the noncleft side, and if release of the lateral nasal wall and reconstruction of the nasal component of the orbicularis oris muscle have not been achieved at the primary lip repair, the nasal base will remain attached to the hypoplastic piriform rim, with inferior and posterior malposition.



The fistula between oral and nasal cavities has three distinct boundaries. The nasolabial fistula is located at the apex of the cleft, high up in the labial sulcus, and consists of loose wet labial mucosa transitioning to nasal mucosa. The oronasal fistula extends from the incisive foramen to the alveolar process, and is a transition of attached palatal mucoperiosteum to nasal mucosa. At the corner of these two fistulas, at the alveolar process itself, attached alveolar gingiva is located, which is the only appropriate support lining of erupting teeth. Whichever technique is employed to close the soft tissues of the nasolabial and oronasal fistulas, attached gingival tissue must be present at the anticipated site of eruption to ensure long-term support of the adult teeth.




Diagnosis/patient presentation



Gingivoperiosteoplasty


Prior to undergoing a GPP, the infant with a cleft must be evaluated by the practitioner coordinating the presurgical molding as well as the surgeon who will be performing the GPP. It must be emphasized that not all infants will be candidates for GPP due to individual variations of anatomy. Some infants with particularly wide unilateral clefts can be “mesenchymally deficient.” Compressing and closing the alveolar cleft with molding and a GPP would unnaturally constrict the arch form. Isolated clefts of the primary palate are also difficult to predict if a GPP is possible. Due to the bony fusion of the secondary palate, the alveolar segments are more resistant to presurgical molding, and in some cases cannot be adequately aligned. Finally, in bilateral complete clefts, it is not always possible to align both sides of the premaxilla with the alveolar segments. In this case, one alveolar cleft can undergo a GPP to convert the arch form to a lesser and greater segment similar to a unilateral cleft. Assessment of parallel alveolar molding can be difficult, and benefits from a team presurgical evaluation (Fig. 26.2.) If the alveolar anatomy and presurgical molding outcome are favorable, a GPP can be offered to the family at the same time as the primary lip repair.





Secondary bone grafting


As the patient is approaching the time of secondary bone graft, the craniofacial orthodontist and surgeon should discuss plans for timing of the graft, the fate of adjacent teeth, and the timing of arch expansion. Any dental morbidity such as poor hygiene or caries should be addressed by a pediatric dentist prior to the surgery. In some cases, primary teeth adjacent to the cleft should be extracted 3–6 weeks prior to grafting in order to ensure a viable mucosal seal of the oral surface of the grafted area. In most cases however, the teeth can be preserved until the time of grafting to maximize bone retention, avoid an additional procedure, and be extracted at the grafting surgery.


Arch expansion can be performed either before or after the graft surgery. Preoperative arch expansion allows the orthodontist to take full advantage of the mobility of the two or three ungrafted segments of the alveolus to achieve appropriate maxillary anterior and posterior arch width. When the graft is then placed and heals in the expanded cleft, the continuous maxillary arch form has an optimal relationship with the mandible. A collapsed overlapping alveolar cleft can also benefit from expansion, by increasing the access and visibility of the surgeon to the fistula at time of operation. The disadvantages of presurgical expansion however include overexpansion, such that the alveolar cleft becomes challenging to treat, due to simultaneous expansion of the oronasal fistula and resulting excessive tension on any soft-tissue repair. If an expander is in place at the time of surgery and obstructs the site, then replacement of the device with a custom acrylic retention splint at the time of surgery is indicated. Postoperative expansion should wait 6–8 weeks from the date of surgery, and conventional orthodontic movements should not be attempted before the cleft is grafted, but can start within 3 weeks of surgery.


Debate continues regarding the appropriate timing of a secondary bone grafting. The mixed-dentition phase is variable among patients, but typically falls between ages 6 and 11. Proponents of grafting early in mixed dentition believe that a stable healed graft prior to canine eruption results in a superior bone environment (Fig. 26.3). El Deeb et al.17 found that successful eruption of cuspids though the graft occurred when root formation of the canine adjacent to the cleft was one-fourth to one-half formed at the time of graft placement. Bergland et al.18 found a higher proportion of graft failures and cases with lower interdental septa when grafting was done adjacent to fully erupted teeth compared to just before eruption. In comparison, Long et al. retrospectively performed detailed periapical radiograph analysis of bone formation and found no significant correlation between final graft success and the amount of canine crown eruption in the cleft at the time of grafting.19




Bone morphogenic protein


Recombinant human bone morphogenic protein-2 (rhBMP2) is a mitogen that has been demonstrated to stimulate osteoblastic activity and induce bone nodule formation in animals. It has been approved by the US Food and Drug Administration for clinical use in human spine fusion procedures, and has been shown to decrease nonunion, donor site morbidity, and operating time over autogenous grafting in this population.20 More recent clinical applications have been on patients undergoing alveolar augmentation and implant placement21 and early trials are now underway at individual centers for the treatment of alveolar clefts. The risk–benefit profile of rhBMP2 in these patients will remain unknown for the next decade. Patient selection should therefore be based on enrolment in an institutional review board-approved trial with appropriate consent and evaluation, including oversight by an independent data safety monitoring board.




Alveolar distraction


Successful primary or secondary treatment of the alveolar cleft should obviate the need for alveolar distraction in this patient population. Unfortunately there exist patients with “ungraftable” or “recalcitrant” alveolar clefts that have few options available to them other than undergoing transport distraction osteogenesis (TDO) of alveolar bone.22 The typical patient who falls into this category has unhealthy, scarred gingiva, a large nasolabial and/or oronasal fistula, and a history of repeated unsuccessful bone grafts with infections and exposure. Another possible presentation is a previously grafted maxilla that has severe vertical deficiency along with scarred mucogingiva preventing additional graft augmentation. In both these cases, TDO is a useful tool to have in the cleft armamentarium.


In the wide “ungraftable” cleft patient (Fig. 26.4), a tooth-bearing transport segment can be slowly moved into the gap, closing the fistula and converting the problem into a narrow cleft amenable to traditional secondary grafting. In the vertically deficient alveolus (Fig. 26.5), a transport segment of superior maxillary bone, with or without prior bone augmentation, can be slowly lowered, leveling the alveolar ridge by gradually bringing the scarred attached gingival tissue along with the advancing bone front.




Factors that may have contributed to previous failed surgeries in patients with “recalcitrant” clefts must be carefully considered to avoid the plan for TDO suffering the same fate. Any dental caries or periapical disease must be addressed to minimize the infection risk during the period when the device is in place. Alcohol, smoking, and drug abuse must be ruled out, and the expectations on the patient must be discussed and documented. All current distraction devices require activation by the patient or caregiver and frequent follow-up during the period of activation. Therefore, a patient who is considered unreliable, noncompliant, or unable to return to clinic regularly is not a suitable candidate. TDO is currently reserved for patients past mixed dentition due to the risk to unerupted tooth follicles during the segmental osteotomies. Coordination with the patient’s orthodontist or prosthodontist is essential in order to agree upon the desired goals of the procedure, and the endpoint of activation. Frequently the treatment plan may include arch expansion or tooth extraction, which should be performed prior to the TDO procedure. Written directions and a device-turning log should be carefully explained to the patient to avoid complications during activation. Perioperative chlorhexidine mouthwash should be used during activation with careful dental hygiene with a soft toothbrush.


Feb 21, 2016 | Posted by in General Surgery | Comments Off on Alveolar clefts
Premium Wordpress Themes by UFO Themes